GeneSeq®PLUS without VUS

CPT: Call client services.
Print Share


  • Follow-up gene sequencing
  • Full gene sequencing
  • Partner gene sequencing

Special Instructions

This assay is not currently available in New York state.

Contact an Integrated Genetics laboratory genetic coordinator at 800-255-7357 with any questions.

Expected Turnaround Time

14 - 21 days

Specimen Requirements


Whole blood


10 mL


Yellow-top (ACD-A) tube or lavender-top (EDTA) tube

Storage Instructions

Maintain at room temperature or refrigerate at 4°C.

Causes for Rejection

Frozen specimen; quantity not sufficient for analysis; improper container; yellow-top (ACD-B) tube

Test Details


Full gene sequencing is available for genes included in the Inheritest®500 PLUS panel. See related Inheritest® test codes: Inheritest® Carrier Screen, Comprehensive (144 genes) (451950); Inheritest® Carrier Screen, Ashkenazi Jewish (48 genes) (451920); Inheritest® Carrier Screen, Society-guided (14 genes) (451960).

For HBA1 and HBA2 (alpha-thalassemis) see α-Thalassemia, DNA Analysis (511172); for SMN1 see Spinal Muscular Atrophy (SMA) Carrier Testing (450010); and for FRM1 see Fragile X Syndrome, PCR with Reflex to Southern Blot (511919). Links to these tests are in Related Information.


Technologies used do not detect germline mosaicism and do not rule out the presence of large chromosomal aberrations, including rearrangements, gene fusions, or variants in regions or genes not included in this test, or possible inter/intragenic interactions between variants. Variant classification and/or interpretation may change over time if more information becomes available. False positive or false negative results may occur for reasons that include: rare genetic variants, sex chromosome abnormalities, pseudogene interference, blood transfusions, bone marrow transplantation, somatic or tissue-specific mosaicism, mislabeled samples, or erroneous representation of family relationships.


Single Nucleotide Polymorphism and Small Indel Sequencing Assessment: Genomic regions of interest are selected using a custom capture reagent for target enrichment and sequenced via the Illumina® next generation sequencing platform. Sequencing reads are aligned with the human genome reference GRCh37/hg19 build. Regions of interest include all exons and intron/exon junctions (+/-20 nucleotides) for each gene analyzed. A minimum of 99% of bases are covered at >15X. Analytical sensitivity is estimated to be >99% for single nucleotide variants, >97% for insertions/deletions less than six base pairs, and >95% for insertions/deletions between six and fifteen base pairs. Uncovered regions with known pathogenic variants are sequenced in a targeted manner. All reported variants are confirmed by a second method.

Copy Number Variant Assessment: Next Generation Sequencing is performed and the data are assessed with Illumina’s DRAGEN (Dynamic Read Analysis for GENomics) Bio-IT Platform. Reported variants are confirmed by a second method. Analytical sensitivity is estimated to be >95%.

Spinal Muscular Atrophy: This analysis will detect the copy number of exon 7 of the SMN1 gene. When no copies of SMN1 exon 7 are detected, SMN2 exon 7 copy number is assessed and reported. This test is unable to differentiate between two copies of the SMN1 gene on one allele (in cis) versus two copies of the gene on different alleles (in trans). When two copies of SMN1 exon 7 are detected, the data are assessed for the presence of the c.*3+80T>G “silent carrier” variant.

Congenital Adrenal Hyperplasia: This analysis will detect most large rearrangements/deletions/duplications within the CYP21A2 gene, as well as the presence of seven of the most common pathogenic variants in the gene: 1) c.518T>A (p.Ile173Asn), Chr6:32007203; 2) c.713T>A (p.Val238Glu); Chr6:32007587; 3) c.719T>A (p.Met240Lys); Chr6:32007593; 4) c.923dup (p.Leu308Phefs); Chr6:32007966; 5) c.293-13C/A>G; Chr6:32006858; 6) c.332_339delGAGACTAC (p.Gly111Valfs); Chr6:32006910-32006917; 7) c.-113G>A; Chr6:32006087. Other point mutations and small indels and reciprocal changes between CYP21A2 and CYP21A1P are not detected by this analysis. The analytical sensitivity of this assay is estimated to be >99%.

Alpha thalassemia: Variants included in the analysis of the alpha-globin (HBA) gene cluster are the Constant Spring non-deletion variant and the following deletions: -alpha3.7, -alpha4.2, --alpha20.5, --SEA, --FIL, --THAI, --MED, and the HS-40 regulatory region.

Reported Variants: Pathogenic and likely pathogenic variants are reported after confirmation by an appropriate technology. NEB variants occurring in exons 82-105 may not be reliably detected by this analysis and are not reported. Nondeletion variants are specified using the numbering and nomenclature recommended by the Human Genome Variation Society. Variants of uncertain significance, likely benign, and benign variants are not reported. Variant classification is consistent with ACMG standards and guidelines.


den Dunnen JT. Describing Sequence Variants Using HGVS Nomenclature. Methods Mol Biol. 2017;1492:243-251.27822869
Monaghan KG, Lyon E, Spector EB; American College of Medical Genetics and Genomics. ACMG Standards and Guidelines for fragile X testing: a revision to the disease-specific supplements to the Standards and Guidelines for Clinical Genetics Laboratories of the American College of Medical Genetics and Genomics. Genet Med. 2013 Jul;15(7):575-586.23765048
Richards S, Aziz N, Bale S. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015 May;17(5):405-424.25741868

For Providers

Please login to order a test.


© 2019  Laboratory Corporation of America® Holdings and Lexi-Comp Inc. All Rights Reserved.

CPT Statement/Profile Statement

The LOINC® codes are copyright © 1994-2018, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. Permission is granted in perpetuity, without payment of license fees or royalties, to use, copy, or distribute the LOINC® codes for any commercial or non-commercial purpose, subject to the terms under the license agreement found at Additional information regarding LOINC® codes can be found at, including the LOINC Manual, which can be downloaded at